Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy (original) (raw)
Figure 3
Mean Percent Change from Baseline to Week 28.
Error bars indicate 95% CI. Placebo (n = 18); mipomersen 200 mg weekly (n = 39). (A) Low-density lipoprotein cholesterol (LDL-C) (B) Apolipoprotein B (Apo B) (C) Lipoprotein(a) (Lp(a)) (D) Non-high density lipoprotein cholesterol (non-HDL-C) (E) Total Cholesterol.